Next Article in Journal
Risk Stratification, Treatment Selection, and Transplant Eligibility in Multiple Myeloma: A Qualitative Study of the Perspectives and Self-Reported Practices of Oncologists
Previous Article in Journal
A Retrospective Analysis of the Role of Proton Pump Inhibitors in Colorectal Cancer Disease Survival
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 23
Issue 6
10.3747/co.23.3273
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Treatment Patterns and Survival in Patients with ALK-Positive Non-small-Cell Lung Cancer: A Canadian Retrospective Study

by
S. Kayaniyil
1,*,
M. Hurry
2,
J. Wilson
1,
P. Wheatley-Price
3,
B. Melosky
4,
J. Rothenstein
5,
V. Cohen
6,
C. Koch
2,
J. Zhang
7,
K. Osenenko
1 and
G. Liu
8
1
ICON Hltha Econ & Epidemiol, 450-688 W Hastings St, Vancouver, BC V6B 1P1, Canad
2
Novartis Pharmaceut Canada, Dorval, PQ, Canada
3
Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada
4
Univ British Columbia, Div Med Oncol, Vancouver, BC, Canada
5
Lakeridge Hlth, Rsm Durham Reg Canc Ctr, Oshawa, ON, Canada
6
Jewish Gen Hosp, Dept Oncol, Montreal, PQ, Canada
7
Novartis Pharmaceut, E Hanover, NJ, USA
8
Princess Margaret Canc Ctr, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2016, 23(6), 589-597; https://doi.org/10.3747/co.23.3273
Submission received: 4 September 2016 / Revised: 3 October 2016 / Accepted: 2 November 2016 / Published: 1 December 2016

Abstract

Background Crizotinib was the first agent approved for the treatment of anaplastic lymphoma kinase (ALK)– positive (+) non-small-cell lung cancer (NSCLC), followed by ceritinib. However, patients eventually progress or develop resistance to crizotinib. With limited real-world data available, the objective of the present work was to evaluate treatment patterns and survival after crizotinib in patients with locally advanced or metastatic ALK+ NSCLC in Canada. Methods In this retrospective study at 6 oncology centres across Canada, medical records of patients with locally advanced or metastatic ALK+ NSCLC were reviewed. Demographic and clinical characteristics, treatments, and outcomes data were abstracted. Analyses focused on patients who discontinued crizotinib treatment. Results Of the 97 patients included, 9 were crizotinib-naïve, and 39 were still receiving crizotinib at study end. The 49 patients who discontinued crizotinib treatment were included in the analysis. Of those 49 patients, 43% received ceritinib at any time, 20% subsequently received systemic chemotherapy only (but never ceritinib), and 37% received no further treatment or died before receiving additional treatment. Median overall survival from crizotinib discontinuation was shorter in patients who did not receive ceritinib than in those who received ceritinib (1.7 months vs. 20.4 months, p < 0.001). In a multivariable analysis, factors associated with poorer survival included lack of additional therapies (particularly ceritinib), male sex, and younger age, but not smoking status; patients of Asian ethnicity showed a nonsignificant trend toward improved survival. Conclusions A substantial proportion of patients with ALK+ NSCLC received no further treatment or died before receiving additional treatment after crizotinib. Treatment with systemic agents was associated with improved survival, with ceritinib use being associated with the longest survival.
Keywords: Crizotinib; ceritinib; lung cancer; ALK-positive non-small-cell lung cancer; treatment patterns; survival Crizotinib; ceritinib; lung cancer; ALK-positive non-small-cell lung cancer; treatment patterns; survival

Share and Cite

MDPI and ACS Style

Kayaniyil, S.; Hurry, M.; Wilson, J.; Wheatley-Price, P.; Melosky, B.; Rothenstein, J.; Cohen, V.; Koch, C.; Zhang, J.; Osenenko, K.; et al. Treatment Patterns and Survival in Patients with ALK-Positive Non-small-Cell Lung Cancer: A Canadian Retrospective Study. Curr. Oncol. 2016, 23, 589-597. https://doi.org/10.3747/co.23.3273

AMA Style

Kayaniyil S, Hurry M, Wilson J, Wheatley-Price P, Melosky B, Rothenstein J, Cohen V, Koch C, Zhang J, Osenenko K, et al. Treatment Patterns and Survival in Patients with ALK-Positive Non-small-Cell Lung Cancer: A Canadian Retrospective Study. Current Oncology. 2016; 23(6):589-597. https://doi.org/10.3747/co.23.3273

Chicago/Turabian Style

Kayaniyil, S., M. Hurry, J. Wilson, P. Wheatley-Price, B. Melosky, J. Rothenstein, V. Cohen, C. Koch, J. Zhang, K. Osenenko, and et al. 2016. "Treatment Patterns and Survival in Patients with ALK-Positive Non-small-Cell Lung Cancer: A Canadian Retrospective Study" Current Oncology 23, no. 6: 589-597. https://doi.org/10.3747/co.23.3273

APA Style

Kayaniyil, S., Hurry, M., Wilson, J., Wheatley-Price, P., Melosky, B., Rothenstein, J., Cohen, V., Koch, C., Zhang, J., Osenenko, K., & Liu, G. (2016). Treatment Patterns and Survival in Patients with ALK-Positive Non-small-Cell Lung Cancer: A Canadian Retrospective Study. Current Oncology, 23(6), 589-597. https://doi.org/10.3747/co.23.3273

Article Metrics

Back to TopTop